Sr. Director, Contract Strategy, Pricing & Operations

Menarini Stemline; United States; On-site; USD 253,000 - 305,000; Full time

Benefits offered by this job

401(k) matching

Health insurance

Job summary

Menarini Stemline is seeking a senior leader to drive US pricing strategy, GTN analytics, and contracting for oncology/hematology therapies such as Orserdu and Elzonris.

You will align brand, finance, and market access teams, oversee deal analytics, and ensure compliance with federal and state pricing regulations in a high-scrutiny market.

Qualifications

• Bachelor’s degree; preferably in Marketing, Science, Economics, Finance or related field.
• 10 years of related healthcare business experience.
• Experience in Oncology/Specialty across small and large molecules.

Responsibilities

• Lead US pricing and life-cycle strategy for key oncology/hematology products.
• Develop deal analytics, GTN models, and contracting frameworks.
• Ensure 100% compliance with government pricing regulations and state transparency.

Skills

Pricing strategy

GTN modeling

Contracting analytics

Leadership & team management

Government pricing compliance

Market access knowledge

Education

Bachelor's degree

Job description

This is a critical leadership position dedicated to driving market access, pricing strategy, and contracting for our best-in-class oncology and hematology therapies. In this high-impact role, you will spearhead US pricing and life-cycle strategies for key products, including Orserdu and Elzonris. Acting as the strategic and financial linchpin between brand, finance, and market access teams, you will lead the team responsible for executing complex deal analytics, optimizing gross-to-net (GTN) performance, and designing comprehensive contracting frameworks to remove access barriers across payors, Specialty Pharmacy Networks, and GPOs. Furthermore, you will champion operational excellence by leading a dedicated team to ensure 100% compliance with government pricing regulations—expertly navigating state transparency laws, 340B impacts, and Medicaid models to secure our market leadership in a high-scrutiny sector.

Responsibilities:

Pricing Strategy, Financial Modeling & Gross-to-Net (GTN)

• Spearhead US pricing for Orserdu and life-cycle strategy for Elzonris, establishing value benchmarks and market leadership for best-in-class oncology and hematology therapies.
• Formulate, model, and execute price changes for Orserdu and Elzonris, routing PI communications and compendia submissions through internal stakeholders.
• Manage quarterly and monthly GTN analyses and breakouts for leadership review.
• Lead the development of deal analytics and scenario models to assess profitability, rebate structures, and Gross-to-Net (GTN) impacts across all commercial channels.
• Coordinate with brand and finance to deliver segment specific insight/modeling to help inform contract strategy development and impact.
• Serves as a resource for Licensing and Business Development in assessing price for potential opportunities.
• In coordination with Market Access field teams, develops contracting and pricing strategies to ensure profitable uptake of the Stemline portfolio.
• Establish portfolio-level guardrails and decision frameworks to optimize access across payors, GPOs, specialty distributors, and large provider networks.
• Lead contracting strategy workshops with payor team, and GPO team to remove any access barriers for Orserdu.
• Designing Payer Contracting Deal Analytics models for Commercial and Medicare lines of business, sales forecasts by payer plan, and establishing standard MSA/Proposal templates.
• Works closely with Account teams to negotiate and implement contracting strategies and ensures implementation of contract strategies and contracting platforms.
• In coordination with the commercial trade and distribution team, develops and/or manages Specialty Pharmacy Networks strategy and performance based on aligned brand strategies.
• Will work closely with Market Access field teams and Medical Affairs to develop and evaluate Value Based Arrangements.

Government Pricing, Programs & State Transparency

• Manage a team ensuring 100% compliance with state drug price transparency regulations and government price reporting, effectively mitigating audit risks in the high-scrutiny oncology sector.
• Lead 340B analysis of distribution changes, contracting initiatives, as well as new federal and state legislation.
• Oversee Orserdu and Elzonris Medicaid waterfall models.
• Responsible for Federal Supply Schedule (FSS) contract renewals and contract adherence.
• Oversight of State Price Transparency Reporting including collaborating to maintain the state disclosure (e.g., CT, VT, and CO).
• Oversee the Pharmaceutical Product Stewardship Work Group program enrollment, tracking state forms, and ensuring timely invoice payments.
• Coordinate with internal and external resources regarding operational activities such as rebates, chargebacks, government reporting, contract writing, and process approvals.
• Evaluate the impact of governmental pricing proposals, policies, and regulations (e.g., Most Favored Nation).
• Support public policy strategy in partnership with Government Affairs by assisting with public comment periods and advocating for small manufacturers.
• Quantify the financial implications of healthcare reform (e.g., Medicare Part D redesign, inflation rebates, MFN) on the pipeline to inform long-term pricing and contracting tradeoffs.

Market Intelligence & Field Enablement

• Deep understanding of payer environment (both medical and pharmacy benefit), competitive market conditions that affect pricing for our oncology products and the pharmaceutical industry overall.
• Translate complex pricing, contracting, and policy landscape shifts into actionable intelligence and tactical materials for field teams.
• Ensure field readiness for negotiations and optimizing formulary access that can result in pull-through initiatives while safeguarding GTN targets.
• Monitors environment and practices for shifts in trends or behaviors and interprets likely impact and suggests appropriate actions.
• Evaluate changing marketplace and proactively make recommendations on pricing strategies as related to managed care, reimbursement environment, federal and state regulations.
• Leading the onboarding, 30-60-90-day planning, equipment setup, and mid-year reviews for your direct report(s).
• Creating and updating regular slide decks and dashboard templates for leadership review.
• Handling the negotiation, signature, and budget approvals for key consulting partners.
• Securing and managing data streams across multiple pharmaceutical solution providers.

Qualifications:

• Bachelor’s degree; preferably in a relevant field (Marketing, Science, Economics, finance or related field).
• 10 years of related healthcare business experience.
• Experience in Oncology/Specialty across small and large molecules
• In depth understanding of Market Access and Healthcare delivery.
• Analytical skills including problem solving, forecasting, contract development and financial modeling.
• Demonstrated negotiation and relationship building skills.
• Demonstrated ability to manage multiple priorities.
• Strong oral and written communication skills, including a strong focus on customer service.
• High level of expertise in Government Pricing

Base Salary Range of $253,000-$305,000. Menarini Stemline offers generous compensation and benefits packages, including Short- and Long-Term Incentive Programs, Fidelity 401(k) (with 6% company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.

About us:

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.